Inotuzumab Ozogamicin
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 537 publications
Lymphoid blast crisis in chronic myeloid leukemia after long-term treatment-free remission following imatinib treatment
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: May 13, 2026
Retrospective analysis of inotuzumab-associated hepatotoxicity in adult patients with B-cell acute lymphoblastic leukemia: Expanding the Spectrum of calicheamicin syndrome.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: April 10, 2026
Incidence of Clinically Significant Neutropenia and Complications Related to Antibody-Drug Conjugates: A Real-World Study at the University of California.
Journal: Cancers
Published: April 01, 2026
Treatment outcomes of adult B-cell ALL with post-transplant relapse in the era of immunotherapeutic agents.
Journal: Transplantation and cellular therapy
Published: March 24, 2026
Low SOS/VOD Risk with Inotuzumab Ozogamicin as a Bridging Strategy to Second Allogeneic HSCT: A Real-World Study in Post-Transplant Relapsed B-ALL.
Journal: Transplantation and cellular therapy
Published: March 16, 2026
Assessment of Risks and Outcomes of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Stem Cell Transplant Recipients Including Potentially Undiagnosed Cases-A Multicenter Canadian Study.
Journal: Current oncology (Toronto, Ont.)
Published: March 01, 2026
Ph-Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs.
Journal: European journal of haematology
Published: February 06, 2026
Chemotherapy-Free Achievement of Minimal Residual Disease in a Jehovah's Witness Patient With Ph-Negative B-ALL.
Journal: The American journal of case reports
Published: January 31, 2026
Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.
Journal: The Lancet. Haematology
Published: January 27, 2026
Brexu-cel cell therapy and subsequent allogeneic hematopoietic stem cell transplantation in the treatment of late-relapse B-cell acute lymphoblastic leukemia
Journal: Recenti progressi in medicina
Published: January 22, 2026
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis.
Journal: American journal of hematology
Published: January 07, 2026
Efficacy and safety of inotuzumab ozogamicin as the definitive therapeutic option prior to allogeneic hematopoietic stem cell transplantation for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia.
Journal: Leukemia & lymphoma
Published: January 07, 2026
Last Updated: 06/30/2026